A Bayesian Network-Based Framework for Causal Cancer Drug Target Discovery Integrating Patient and Cell Line Data
Current approaches to cancer drug target discovery face two key limitations: poor translation of cell line-derived targets to patient tumors, and the lack of causal explanation of the regulatory mechanisms underlying target prioritization. Here we present BayesTx (Bayesian Therapeutics target discovery), a Bayesian network framework that integrates patient transcriptomics data with cell line data to identify causal therapeutic targets in cancer. BayesTx projects both data domains into a shared biological space of pathway and transcription factor activities, learns domain-specific causal graphs, and merges them through weighted edge aggregation with bootstrap consensus filtering. Do-simulation on the consensus network quantifies the causal effect of each transcription factor on cancer cell viability. Applied to breast cancer using TCGA-BRCA (The Cancer Genome Atlas breast cancer cohort) and DepMap (Cancer Dependency Map) datasets, the framework ranked 47 transcription factors by predicted causal impact, with gene-level targets further derived through regulon-based propagation. Top-ranked transcription factor (TF) targets were independently supported by survival analysis in external cohort data and pharmacogenomic drug response associations. Overall, BayesTx demonstrates that cross-domain Bayesian network modeling can bridge patient and cell line data to systematically identify causal therapeutic targets in cancer.